FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887980387> ?p ?o ?g. }

• W2887980387 abstract "Giant cell tumor of bone (GCTB) is an intermediate tumor known to be locally aggressive, but rarely metastasizing. To plan a prospective study of GCTB, we performed a questionnaire survey for institutions participating in the Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) in 2015.We reviewed 158 consecutive patients with primary GCTB treated with curettage without perioperative denosumab from 2008 to 2010 in Japan. We investigated local and distant recurrence rates after definitive curettage. We also investigated the recurrence rate after treatment with preoperative and/or postoperative denosumab with curettage in recent years. There were 40 patients treated with perioperative denosumab, and the factors affecting recurrence in them were investigated.Answers were available from 24 of 30 institutions (80.0%) participating in JCOG BSTTSG. Thirty (19.0%) and 4 (2.5%) of 158 patients developed local and distant recurrence after curettage without perioperative denosumab from 2008 to 2010, respectively. Campanacci grade and embolization before surgery were significantly associated with increasing incidence of local recurrence after curettage (p = 0.034 and p = 0.022, respectively). In patients treated with perioperative desnosumab, 120 mg denosumab was administered subcutaneously for a median 6 (2-41) and 6 (1-14) times in preoperative and postoperative settings, respectively. The recurrence rates were 6 of 21 (28.6%), 2 of 9 (22.2%), and 0 of 10 (0.0%) in the preoperative, postoperative, and both pre- and postoperative denosumab treatment groups, respectively. With all of the preoperative treatments, administration exceeding five times was significantly associated with a decreased incidence of local recurrence after curettage (p < 0.001).The recurrence rate of GCTB was still high after curettage, especially in Campanacci grade III, and improvements in the therapeutic strategy are needed in this cohort. There is a possibility that a sufficient dose of preoperative denosumab can reduce recurrence after curettage. Recently, we have started a clinical trial, JCOG1610, to investigate the efficacy of preoperative denosumab in patients who can be treated with curettage in GCTB." @default.
• W2887980387 created "2018-08-22" @default.
• W2887980387 creator A5001042153 @default.
• W2887980387 creator A5005444399 @default.
• W2887980387 creator A5011966088 @default.
• W2887980387 creator A5013573447 @default.
• W2887980387 creator A5018580532 @default.
• W2887980387 creator A5019295234 @default.
• W2887980387 creator A5020130249 @default.
• W2887980387 creator A5021371159 @default.
• W2887980387 creator A5021462550 @default.
• W2887980387 creator A5022274058 @default.
• W2887980387 creator A5022829110 @default.
• W2887980387 creator A5022969997 @default.
• W2887980387 creator A5023589754 @default.
• W2887980387 creator A5027207215 @default.
• W2887980387 creator A5032143524 @default.
• W2887980387 creator A5036808755 @default.
• W2887980387 creator A5037090618 @default.
• W2887980387 creator A5037472971 @default.
• W2887980387 creator A5037676006 @default.
• W2887980387 creator A5051492014 @default.
• W2887980387 creator A5053792537 @default.
• W2887980387 creator A5054299469 @default.
• W2887980387 creator A5054828220 @default.
• W2887980387 creator A5056088790 @default.
• W2887980387 creator A5056871540 @default.
• W2887980387 creator A5059050136 @default.
• W2887980387 creator A5076919182 @default.
• W2887980387 creator A5087421653 @default.
• W2887980387 date "2018-08-08" @default.
• W2887980387 modified "2023-10-06" @default.
• W2887980387 title "Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study" @default.
• W2887980387 cites W1507649428 @default.
• W2887980387 cites W1965247641 @default.
• W2887980387 cites W1967985607 @default.
• W2887980387 cites W1968663581 @default.
• W2887980387 cites W2001910174 @default.
• W2887980387 cites W2008801118 @default.
• W2887980387 cites W2028541032 @default.
• W2887980387 cites W2034585055 @default.
• W2887980387 cites W2075593962 @default.
• W2887980387 cites W2076395246 @default.
• W2887980387 cites W2093956992 @default.
• W2887980387 cites W2100888640 @default.
• W2887980387 cites W2101687609 @default.
• W2887980387 cites W2105046527 @default.
• W2887980387 cites W2117125451 @default.
• W2887980387 cites W2123114700 @default.
• W2887980387 cites W2128154445 @default.
• W2887980387 cites W2129142927 @default.
• W2887980387 cites W2159152276 @default.
• W2887980387 cites W2267781735 @default.
• W2887980387 cites W2284524509 @default.
• W2887980387 cites W2414485509 @default.
• W2887980387 cites W2793466037 @default.
• W2887980387 cites W2989258869 @default.
• W2887980387 cites W4292542148 @default.
• W2887980387 doi "https://doi.org/10.1186/s12957-018-1459-6" @default.
• W2887980387 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6083623" @default.
• W2887980387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30089488" @default.
• W2887980387 hasPublicationYear "2018" @default.
• W2887980387 type Work @default.
• W2887980387 sameAs 2887980387 @default.
• W2887980387 citedByCount "35" @default.
• W2887980387 countsByYear W28879803872018 @default.
• W2887980387 countsByYear W28879803872019 @default.
• W2887980387 countsByYear W28879803872020 @default.
• W2887980387 countsByYear W28879803872021 @default.
• W2887980387 countsByYear W28879803872022 @default.
• W2887980387 countsByYear W28879803872023 @default.
• W2887980387 crossrefType "journal-article" @default.
• W2887980387 hasAuthorship W2887980387A5001042153 @default.
• W2887980387 hasAuthorship W2887980387A5005444399 @default.
• W2887980387 hasAuthorship W2887980387A5011966088 @default.
• W2887980387 hasAuthorship W2887980387A5013573447 @default.
• W2887980387 hasAuthorship W2887980387A5018580532 @default.
• W2887980387 hasAuthorship W2887980387A5019295234 @default.
• W2887980387 hasAuthorship W2887980387A5020130249 @default.
• W2887980387 hasAuthorship W2887980387A5021371159 @default.
• W2887980387 hasAuthorship W2887980387A5021462550 @default.
• W2887980387 hasAuthorship W2887980387A5022274058 @default.
• W2887980387 hasAuthorship W2887980387A5022829110 @default.
• W2887980387 hasAuthorship W2887980387A5022969997 @default.
• W2887980387 hasAuthorship W2887980387A5023589754 @default.
• W2887980387 hasAuthorship W2887980387A5027207215 @default.
• W2887980387 hasAuthorship W2887980387A5032143524 @default.
• W2887980387 hasAuthorship W2887980387A5036808755 @default.
• W2887980387 hasAuthorship W2887980387A5037090618 @default.
• W2887980387 hasAuthorship W2887980387A5037472971 @default.
• W2887980387 hasAuthorship W2887980387A5037676006 @default.
• W2887980387 hasAuthorship W2887980387A5051492014 @default.
• W2887980387 hasAuthorship W2887980387A5053792537 @default.
• W2887980387 hasAuthorship W2887980387A5054299469 @default.
• W2887980387 hasAuthorship W2887980387A5054828220 @default.
• W2887980387 hasAuthorship W2887980387A5056088790 @default.
• W2887980387 hasAuthorship W2887980387A5056871540 @default.
• W2887980387 hasAuthorship W2887980387A5059050136 @default.
• W2887980387 hasAuthorship W2887980387A5076919182 @default.
• W2887980387 hasAuthorship W2887980387A5087421653 @default.

• next